MONTREAL, Oct. 3, 2013 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by the early warning requirements of applicable Canadian securities laws. Paul Averback MD announces today that he has sold in a private transaction for financial planning purposes 372,866 common shares of Nymox Pharmaceutical Corporation (“Nymox”) for a total consideration of $2,400,000 US ($2,479,902 CDN).
Help employers find you! Check out all the jobs and post your resume.